Musculoskeletal Health in Premature Ovarian Insufficiency. Part One: Muscle.


Journal

Seminars in reproductive medicine
ISSN: 1526-4564
Titre abrégé: Semin Reprod Med
Pays: United States
ID NLM: 100909394

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 9 1 2021
medline: 15 12 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

Accelerated bone loss and muscle decline coexist in women with premature ovarian insufficiency (POI), but there are significant gaps in our understanding of musculoskeletal health in POI. This article is the first of a two-part review which describes estrogen signaling in muscle and its role in musculoskeletal health and disease. Current evidence regarding the utility of available diagnostic tests and therapeutic options is also discussed. A literature review from January 2000 to March 2020 was conducted to identify relevant studies. Women with POI experience significant deterioration in musculoskeletal health due to the loss of protective effects of estrogen. In addition to bone loss, muscle decay and dysfunction is now increasingly recognized. Nevertheless, there is a paucity of validated tools to assess muscle parameters. There is a growing need to acknowledge bone-muscle codependence to design new therapies which target both muscle and bone, resulting in improved physical performance and reduced morbidity and mortality. More high-quality research and international collaborations are needed to address the deficiencies in our understanding and management of musculoskeletal health in women with POI.

Identifiants

pubmed: 33418593
doi: 10.1055/s-0040-1721797
doi:

Substances chimiques

Estrogens 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-288

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Navira Samad (N)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Department of Endocrinology, Monash Health, Clayton, Victoria, Australia.
Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia.

Hanh H Nguyen (HH)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Department of Endocrinology, Monash Health, Clayton, Victoria, Australia.
Department of Endocrinology and Diabetes, Western Health, Victoria, Australia.

David Scott (D)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia.

Peter R Ebeling (PR)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Department of Endocrinology, Monash Health, Clayton, Victoria, Australia.

Frances Milat (F)

Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Department of Endocrinology, Monash Health, Clayton, Victoria, Australia.
Department of Endocrinology and Diabetes, Western Health, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH